Navigation Links
Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
Date:6/1/2009

tiple myeloma: Preliminary results" (Abstract #8541).

About Multiple Myeloma

According to the American Cancer Society, in 2009, approximately 20,500 new cases of multiple myeloma will be diagnosed in the United States. Newly diagnosed patients have treatment options that include combination chemotherapeutic agents and stem cell transplantation. While many patients respond to treatment, most eventually relapse and require subsequent treatment. Few patients are ultimately cured of their disease. In spite of advances in the treatment of multiple myeloma, this year alone, approximately 10,500 patients are expected to die of the disease.

About Carfilzomib

Carfilzomib is the first in a new class of selective, irreversible proteasome inhibitors. Carfilzomib produces specific and sustained inhibition of the proteasome, leading to apoptosis in cancer cells with minimal off-target effects. In Phase 1 and Phase 2 clinical trials, carfilzomib has demonstrated single-agent activity in hematologic malignancies and solid tumors, including multiple myeloma, Waldenstrom's macroglobulinemia, mantle cell lymphoma and renal cell carcinoma.

Proteolix is conducting a comprehensive clinical development program evaluating carfilzomib for the treatment of multiple myeloma, including an ongoing accelerated approval study in heavily pre-treated relapsed/refractory patients and a Phase 2 clinical trial in relapsed patients stratified by prior treatment with bortezomib. Both Phase 2 clinical trials are being conducted by Proteolix in collaboration with the Multiple Myeloma Research Consortium (MMRC). A Phase 1b clinical trial of carfilzomib in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma is also ongoing. In addition, Proteolix is conducting a single-agent Phase 2 clinical trial of carfilzomib in patients with recurrent or advanced solid tumors. For the la
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
2. Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
3. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
4. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
5. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
8. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
9. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
10. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
11. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015   HeartWare International, Inc . (NASDAQ: ... support technologies that are revolutionizing the treatment of advanced heart ... , is scheduled to present at the Bank of America ... Vegas on Thursday, May 14, 2015, at 10:00 ... of the Company,s presentation at the conference will be available ...
(Date:5/4/2015)... 2015 MEI Pharma, Inc. (Nasdaq: ... clinical development of novel therapies for cancer, today ... the Company,s investigational drug candidate ME-344 in cancer ... with a tyrosine-kinase inhibitor (TKI). In addition, a ... potent inhibitor of mitochondrial oxidative phosphorylation (OXPHOS) complex ...
(Date:5/4/2015)... 2015 Dyadic International, Inc. ("Dyadic") (OTCQX: ... proprietary technologies are used to develop, manufacture and ... bio-based chemical, biopharmaceutical and industrial enzyme industries, announced ... for quarter ending March 31, 2015 after market ... host a conference call that day at 5:00 ...
Breaking Medicine Technology:HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 2Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 3
... The University HealthSystem Consortium (UHC) today announced an agreement with Centurion Service ... services. The contract was effective on February 1, 2010 . , ... Centurion, the world,s largest medical auction house with ... assists UHC members in the setup and management of their surplus asset programs ...
... (NYSE: ABT ) will present at the 26th Annual Sanford Bernstein ... York City .  Miles D. White, chairman and chief executive officer, will make ... , , , ... presentation will be accessible through Abbott,s Investor Relations Web site at www.abbottinvestor.com ...
Cached Medicine Technology:University HealthSystem Consortium Selects Centurion Service Group for Equipment and Asset Liquidation Services 2
(Date:5/3/2015)... Metamora, Michigan (PRWEB) May 03, 2015 ... mark on their Facebook page. , Their ... on the many services the Practice has, it’s multiple ... events. , Women’s Excellence has a very strong social ... Pinterest, Instagram and You Tube. , Women’s Excellence ...
(Date:5/3/2015)... (PRWEB) May 03, 2015 Leading international ... announced it will be awarding the 2015 Harris Wofford ... and Selemawit Ghebrendrias, are the deserving recipients of the ... global service, Harris Llewellyn Wofford. The two recipients were ... passion for global health. , CFHI is one ...
(Date:5/3/2015)... (PRWEB) May 03, 2015 Indiana Fiber ... Provider announces Bank Computer Services, Inc (BCS) has selected ... BCS’ President states, “The technology, service, and working relationship ... like is the local feel you get with IFN. ... managed company; IFN makes local decisions and operates as ...
(Date:5/3/2015)... Missouri (PRWEB) May 03, 2015 ... business that will directly impact your career? The ... designed for dynamic leaders in multinational companies and ... company. In a changing global landscape, differences in ... and relationships. The EMIB program develops the global ...
(Date:5/3/2015)... (PRWEB) May 03, 2015 SpineFrontier, a ... from the FDA to produce and market their new ... can be used in outpatient settings and is compatible ... alternate posterior approach has been extensively researched and refined ... approval to use this approach in conjunction with a ...
Breaking Medicine News(10 mins):Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 2Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 3Health News:Bank Computer Services, Inc Selects Indiana Fiber Network, LLC as Fiber Transport Provider 2Health News:Bank Computer Services, Inc Selects Indiana Fiber Network, LLC as Fiber Transport Provider 3Health News:The Saint Louis University's Master of International Business Is Now Enrolling For Fall 2015 2
... prolonged air journeys could expose the passengers to risk ... United Nations //health agency has issued fresh guidelines to ... resistant tuberculosis must postpone any long distance air travel, ... no case of active TB has been identified due ...
... been receiving incessant calls from four groups, which represent ... hepatitis C after receiving contaminated blood products, to reject ... standing issue of insurance. , Health Minister, ... a bill to establish a statutory scheme that would ...
... have announced a new test to identify patients who ... could be at fault is unveiled ,today//. ,An ... their report in the New England Journal of Medicine. They ... these patients could then get the best treatment and will ...
... experts have written an open letter in the Scotsman newspaper ... rumors// that MMR Vaccine was linked to autism. ... the UK could face a serious situation with outbreaks of ... of "any association between MMR and autism" should be effectively ...
... rehabilitation system that can perform a variety of ... cricket captain Dilip Vengsarkar here Tuesday//. ,PrimusRS, ... measure the performance, recovery, and fitness-levels of sportspersons. ... participation in the international sporting arena has sports ...
... reduce the risks associated with erectile dysfunction and other ... School of Public Health (HSPH) revealed a positive correlation ... a negative correlation with regular physical activity and healthy ... the Harvard School of Public Health (HSPH) has found ...
Cached Medicine News:Health News:A New Test Developed to Identify Suspected Bowel Cancer Patients 2Health News:Erectile Dysfunction Linked with Smoking and Obesity – Study Report 2
... somatomedin-C, is a peptide highly dependent on ... activity. IGF-I is transported in serum by ... growth disorders, measurements of IGF-I are a ... secretion. A normal plasma or serum IGF-I ...
... IMMULITE 2500 is a high-throughput immunoassay system ... the IMMULITE 2000 with the important addition ... ,allows assays to be designed for optimal ... ,This allows for critical assays such as ...
... For The Detection Of ... Of C-Peptide Measurement:, ... hypoglycemia , Assisting in ... mellitus , Differentiating insulin ...
... kit is for the quantitative determination of ... the AutoDELFIA Automatic Immunoassay System. C-peptide measurement ... function in patients treated with insulin, to ... diabetes, and various other diagnostic applications in ...
Medicine Products: